Bio-Rad launches rapid drugs screening test:
This article was originally published in Clinica
Executive Summary
Bio-Rad is introducing its TOX/see hand-held toxicology screening device for drugs of abuse, which offers results in three minutes. The FDA-cleared urine sample immunoassay test will be marketed worldwide to hospitals and laboratories as an alternative to automated toxicology tests where volumes are small. The Hercules, California-based company says that the system provides an economical alternative to products already on the market.
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.